Korean Dong-A In Talks With Warner Chilcott For Additional Indications For ED Drug Zydena
This article was originally published in The Pink Sheet Daily
Lower urinary tract symptoms related to prostatic hypertrophy could be next indication.
You may also be interested in...
SEOUL - GlaxoSmithKline is paying KRW142.9 billion ($128.7 million) to acquire a 9.9 percent stake in South Korea's leading Dong-A pharmaceutical and OTC company. The strategic alliance should help GSK gain market share in the rapidly growing Korean pharmaceutical market
With the acquisition of Procter & Gamble's pharma business complete, the specialty drug maker adds 1,900 employees.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.